These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6811355)

  • 21. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay.
    Matsuda A; Kuzuya T; Sugita Y; Kawashima K
    Horm Metab Res; 1983 Sep; 15(9):425-8. PubMed ID: 6416980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.
    Hartmann D; Korn A; Komjati M; Heinz G; Haefelfinger P; Defoin R; Waldhäusl WK
    Br J Clin Pharmacol; 1990 Aug; 30(2):245-52. PubMed ID: 2119677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations.
    Neuvonen PJ; Kivistö KT
    Br J Clin Pharmacol; 1991 Aug; 32(2):215-20. PubMed ID: 1931470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of mitomycin C in dogs: application of a high-performance liquid chromatographic assay.
    Barbhaiya RH; Papp EA; Van Harken DR; Smyth RD
    J Pharm Sci; 1984 Sep; 73(9):1220-3. PubMed ID: 6436466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication.
    Mortensen UM; Nielsen-Kudsk JE; Sondergaard HM; Jakobsen P; Jensen BS; Schmitz O; Nielsen TT
    Diabet Med; 2006 Mar; 23(3):327-30. PubMed ID: 16492219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [14C-Glibenclamide concentrations in serum and 14C-glibenclamide urine excretion in diabetic patients with simultaneous determination of blood glucose and insulin (author's transl)].
    Birk W; Schmidt HA; Petrides P
    Arzneimittelforschung; 1978; 28(2):330-7. PubMed ID: 416832
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of the kinetics of glyburide and its active metabolites in humans.
    Rydberg T; Jönsson A; Melander A
    J Clin Pharm Ther; 1995 Oct; 20(5):283-95. PubMed ID: 8576296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
    Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
    Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of glyburide.
    Pearson JG
    Am J Med; 1985 Sep; 79(3B):67-71. PubMed ID: 3931464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of glibenclamide: a single dose comparison of four preparations in human volunteers.
    Karttunen P; Uusitupa M; Nykänen S; Robinson JD; Sipilä J
    Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):642-6. PubMed ID: 3937815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [High performance liquid chromatographic assay for aceclofenac in plasma and its pharmacokinetics in dogs].
    Liu XQ; Chen XJ; Zhao LH; Peng JH
    Yao Xue Xue Bao; 1997 Jul; 32(7):546-8. PubMed ID: 11596282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute effect of glibenclamide upon red cell transglutaminase activity in diabetic patients.
    Coves MJ; Gomis R; Ribes JL; Arbos MA; Casamitjana R; Vilardell E
    J Endocrinol Invest; 1987 Dec; 10(6):565-8. PubMed ID: 2894389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of galactose in human blood by high-performance liquid chromatography: comparison with an enzymatic method and application to the pharmacokinetic study of galactose in patients with liver dysfunction.
    Hu OY; Hu TM; Tang HS
    J Pharm Sci; 1995 Feb; 84(2):231-5. PubMed ID: 7738808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of chlorpropamide and glibenclamide treatment of maturity-onset diabetes: control assessed by fasting plasma glucose concentrations.
    Ward EA; Lang DA; Phillips MR; Turner RC
    Diabetes Care; 1981; 4(2):293-5. PubMed ID: 6783374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-performance liquid column and thin-layer chromatographic determination of human serum glibenclamide at therapeutic levels.
    Uihlein M; Sistovaris N
    J Chromatogr; 1982 Jan; 227(1):93-101. PubMed ID: 6799533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3).
    Boileau P; Wolfrum C; Shih DQ; Yang TA; Wolkoff AW; Stoffel M
    Diabetes; 2002 Dec; 51 Suppl 3():S343-8. PubMed ID: 12475773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.